Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
Launched by BOSCH HEALTHCARE SOLUTIONS GMBH · Jun 24, 2020
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject is 7 to 80 years of age.
- • 2. Has asthma
- • 3. Has been identified as a candidate for inhaled corticosteroid (ICS) treatment
- • 4. Is willing and able to perform Vivatmo pro™ testing
- Exclusion Criteria:
- • 1. Subject has used corticosteroids prior to enrollment.
- • 2. Subject has other current serious medical conditions
- • 3. Subject has not been clinically stable for at least 2 weeks prior to the study
- • 4. Subject is unwilling or unable to perform Vivatmo pro testing
About Bosch Healthcare Solutions Gmbh
Bosch Healthcare Solutions GmbH is a leading innovator in the healthcare technology sector, dedicated to enhancing patient care through advanced digital solutions. As a subsidiary of the Bosch Group, the company leverages its extensive expertise in engineering and software development to create integrated healthcare systems that improve the efficiency and effectiveness of medical services. Focused on delivering high-quality, patient-centered solutions, Bosch Healthcare Solutions is committed to advancing clinical research and fostering collaboration in the healthcare community to drive transformative outcomes for patients and providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Raleigh, North Carolina, United States
Waco, Texas, United States
Saint Louis, Missouri, United States
Birmingham, Alabama, United States
White Marsh, Maryland, United States
Bakersfield, California, United States
Patients applied
Trial Officials
Klaus Mueller
Study Director
Bosch Healthcare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials